FGen is an emerging Swiss biotech company active as a contract research organization in strain development and optimization. Key technologies are methods for biological engineering, such as Synthetic Biology or non-GMO methods, and a proprietary screening platform for …

Co- founded in 2011 by scientists from Sven Panke’s Bioprocess Lab, FGen designs and optimises biotechnological production strains for sustainable bio- based products. The acquisition represents another major step in D- BSSE’s goal of advancing bio- engineering technologies in life sciences worldwide.

2022年3月14日 · BOSTON and BASEL, Switzerland, March 14, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive...

FGen is an emerging Swiss company that combines biological engineering, such as synthetic biology, metabolic engineering, or non-GMO methods, with high throughput screening to design and optimize...

2022年3月15日 · $Ginkgo Bioworks (DNA)$ 已签署最终协议，收购瑞士生物工程公司FGen AG，该公司以其基于纳升反应器技术的专有超高通量筛选平台而闻名。 Ginkgo Bioworks 认为，FGen的技术将显著增强银杏的细胞筛选能力，并使银杏能够探索更广阔的遗传机会空间，增加找到符合不同产品规格的酶、途径、菌株或细胞系的可能性。 交易条款尚未披露。 该公司表示，FGen将收到预付款以及与成功集成和部署其技术相关的额外或有对价。 $义翘神州 …

2011年1月1日 · FGen is a Swiss start-up company founded 2011 in Basel, Switzerland as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract research organization we collaborate with partners from Biotech, Life Sciences, Agribusiness, and Pharma in order to develop microbes, cells, chemicals, and proteins for ...

2023年12月19日 · 利用FGen强大的筛选技术，能够产生β-乳球蛋白的工程微生物将在FGen进行超高通量测试，利用其尖端平台，可以在一次运行中快速搜索多达100万个HOB变体。

2023年12月19日 · Engineered microbes capable of producing beta-lactoglobulin will undergo ultra-high throughput testing at FGen, leveraging its cutting-edge platform that makes it possible to rapidly search ...

2022年3月14日 · FGen开发了一个建立在纳升反应器技术上的超高通量（uHT）筛选平台。 Ginkgo认为，FGen的技术将大大增强Ginkgo的细胞筛选能力，使Ginkgo能够探索更广阔的遗传机会空间，增加找到符合不同产品规格的酶、途径和菌株或细胞系的可能性。

2022年3月14日 · Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire FGen AG (“FGen”), a Swiss company specializing in strain development and optimization.